CG-400549, also known as CG-0549, is an enoyl-(acyl-carrier protein) reductase fabl inhibitor developed by CrystalGenomics for the treatment of compcolicated acute and methicillin-resistant Staphylococcus aureus. CG400549 shows potent antimicrobial activity against 203 S. aureus strains and was more potent than either linezolid or vancomycin. An animal study showed that CG-400549has potential for the treatment of staphylococcal infections in mice and rats